Kidney Disease

Posttransplant Outcomes Assessed in Patients Who Resumed TNFi Therapy

By October 18, 2018

Of the 5256 patients who received a renal transplant in the study window (1/1/1998 - 12/31/2017), 14 met inclusion criteria.

Hydralazine Linked to Amenorrhea in Premenopausal Patient

By September 18, 2018

This case highlights a possible relationship between the administration of hydralazine and the development of amenorrhea.

Caffeine Consumption Appears to Reduce the Risk of Death in CKD Patients

By September 12, 2018

Using data from the National Health and Nutrition Examination Survey (1999-2010), researchers evaluated caffeine consumption among 4863 non-institutionalized adults with CKD to determine the association between caffeine intake and mortality in these patients.

Bloodless Hyperkalemia Test Gets FDA's Breakthrough Device Designation

By September 12, 2018

The KardiaK Platform works through a deep neural network trained to detect hyperkalemia based on data from electrocardiograms (ECG) similar to those captured by the Company's KardiaMobile and KardiaBand devices.

Oral Semaglutide Appears Safe, Effective in T2D Patients With Renal Impairment

By August 20, 2018

PIONEER 5 (N=324) was a randomized, double-blind, placebo-controlled, parallel-group, 26-week trial that evaluated the safety and efficacy of oral semaglutide 14mg vs placebo in patients with type 2 diabetes and moderate renal impairment (eGFR 30 to 59mL/min/1.73m2) inadequately controlled with metformin, sulfonylurea alone or in combination with metformin, or basal insulin alone or in combination with metformin.

Azedra Approved to Treat Rare Tumors of the Adrenal Gland

By July 31, 2018

Azedra should be used by or under the control of physicians who are qualified by specific training and experience in the safe use and handling of radiopharmaceuticals.

FDA Clears Smartphone-Enabled Urinalysis Kit for Home Use

By July 25, 2018

The Dip.io kit works in tandem with existing smartphone cameras and a dedicated app.

Zemdri Now Available for the Treatment of Complicated UTI, Pyelonephritis

By July 20, 2018

Zemdri carries a Boxed Warning describing reports of nephrotoxicity, ototoxicity, and neuromuscular blockade, as well as fetal harm if administered during pregnancy.

Trulicity Labeling Updated to Include Data on T2D Patients With CKD

By July 19, 2018

In the AWARD-7 trial, patients who received Trulicity 0.75mg or 1.5mg in combination with mealtime insulin lispro achieved similar glycemic control with weight loss vs patients who received traditional basal-bolus insulin.

Canagliflozin Trial for T2D With CKD Stopped Early Due to Positive Results

By July 17, 2018

A clinical trial assessing canagliflozin (Invokana; Janssen) as an addition to standard-of-care in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) has been stopped early after meeting its pre-specified efficacy criteria.

FDA Permits Marketing of Devices to Create Arteriovenous Fistula

July 05, 2018

Two devices designed to create arteriovenous fistula in patients with CKD in need of hemodialysis

Nitric Oxide Cuts Kidney Injury After Long Cardiac Surgery

July 02, 2018

Reduced kidney injury, better kidney function seen after prolonged cardiopulmonary bypass

Dulaglutide Assessed in T2D Patients With Chronic Kidney Disease

By June 20, 2018

In AWARD-7, eligible patients (N=577) were randomized to receive dulaglutide 1.5mg once-weekly (N=193), dulaglutide 0.75mg (N=190) once-weekly, or insulin glargine daily (N=194), all in combination with insulin lispro, for 52 weeks. HbA1c at 26 weeks with a 0.4% non-inferiority margin was designated as the primary outcome, while secondary outcomes included eGFR and urine albumin-to-creatinine ratio.

Many AKI Reports in FAERS Linked to Drugs Not Recognized as Nephrotoxic

By June 12, 2018

According to the authors, this is the first study to identify medications most commonly reported for a specific adverse reaction using this database.

More Rapid Decline in Kidney Function for Diagnosed Diabetes

June 08, 2018

Much steeper decline in adjusted mean eGFR for those with diagnosed diabetes versus those without

Positive Results Announced for First-in-Class Metabolic Acidosis Treatment

By June 05, 2018

After 12 weeks, 59.2% of patients treated with the study drug saw an increased blood bicarbonate of ≥4mEq/L or achieved a level in the normal range (22 to 29mEq/L) vs 22.5% of patients in the placebo group (primary endpoint; P <.0001).

Raviten Gets Fast Track Status for Intradialytic Hypotension Management

By May 29, 2018

Intradialytic hypotension is a common complication of hemodialysis and can lead to increased morbidity and mortality among patients with end-stage renal disease.

Hyperkalemia Treatment Lokelma Gets FDA Approval

By May 21, 2018

Lokelma is a non-absorbed zirconium silicate that preferentially captures potassium in exchange for hydrogen and sodium.

Undisclosed Lab Result Leads to Lawsuit After Patient's Death

By May 02, 2018

Dr P's expert testified that there was nothing to treat or to tell the patient about.

First FDA-Approved Treatment for X-Linked Hypophosphatemia Launched

By April 30, 2018

Crysvita, a recombinant fully human monoclonal IgG1 antibody, works by blocking fibroblast growth factor 23 (FGF23), a hormone that causes phosphate urinary excretion and suppresses vitamin D production by the kidney.

Jynarque Approved to Slow Kidney Function Decline in Patients With ADPKD

By April 25, 2018

The efficacy of tolvaptan was demonstrated in two pivotal trials, lasting one year and three years, respectively.

Carvedilol vs Metoprolol: Mortality Risk Examined Among Hemodialysis Patients

By April 18, 2018

Results showed that compared to metoprolol, those who initiated carvedilol had a greater all-cause (HR, 1.08; 95% CI,1.02-1.16) and cardiovascular mortality (HR, 1.18; 95% CI, 1.08-1.29).

Crysvita Approved for the Treatment of X-Linked Hypophosphatemia

By April 17, 2018

Crysvita is an antibody that blocks fibroblast growth factor 23 (FGF23), a hormone that causes phosphate urinary excretion and suppresses active vitamin D production by the kidney.

Sacubitril/Valsartan May Help Preserve Kidney Function in Patients With HFrEF

By April 16, 2018

Compared with the enalapril-treated group, those treated with sacubitril/valsartan were found to have significantly slower kidney decline (-1.3 vs -1.8mL/min/1.73m2 per year; P<0.0001).

Canagliflozin May Improve Renal Outcomes in Patients With T2D

By April 12, 2018

The renal protective benefit was seen in patients with both reduced (eGFR <60mL/min/1.73m2) and preserved (eGFR ≥60mL/min/1.73m2) renal function.

Add-On Antihypertensives Compared in Patients With Diabetes on ACEIs, ARBs

By March 28, 2018

The composite significant kidney event end point was defined as the first occurrence of ≥30% decline in eGFR to an eGFR <60mL/min/1.73m2, initiation of dialysis or kidney transplant.

Dapagliflozin Evaluated in Patients With T2D and Moderate Renal Impairment

By March 20, 2018

Farxiga is a sodium-glucose co-transporter 2 (SGLT2) inhibitor currently indicated as an adjunct to diet and exercise to improve glycemic control in adults with T2D mellitus.

CDC: Acute Kidney Injury Hospitalization Rates Examined in the U.S.

By March 16, 2018

For the report, AKI was defined as the occurrence of at least 1 diagnostic code 584 (acute renal failure) or the occurrence of at least 1 procedure code of 39.95 (hemodialysis) or 54.98 (peritoneal dialysis).

Regional variation in CT imaging is associated with nephrectomy risk

January 03, 2018

Regional variation in cumulative risk of an individual having a chest or abdominal CT in the United States was positively correlated with the risk of both total and partial nephrectomy, as well as any renal procedure (including renal ablation).

Outcomes after left ventricular assist device implantation significantly worse for those with end-stage renal disease

January 03, 2018

Patients with end-stage renal disease (ESRD) have significantly worse survival outcomes following left ventricular assist device (LVAD) implantation compared to recipients without ESRD.